PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 11, 2026European Journal of Internal Medicine4 citationsOpen Access

Direct oral anticoagulants versus Vitamin K antagonist in kidney transplant recipients with atrial fibrillation: A study from a global federated research network

View Full Paper
MRMichele RossiETEnrico TartagliaAAAmir Askarinejad

Key Result

DOACs use in kidney transplant recipients with atrial fibrillation was associated with lower risk of composite outcomes and kidney transplant rejection.

Key Points

  • Evaluate the effectiveness of direct oral anticoagulants (DOACs) versus vitamin K antagonists in kidney transplant recipients with atrial fibrillation.
  • Analyzed data from a real-world cohort of kidney transplant recipients (KTRs) with atrial fibrillation (AF).
  • Compared outcomes between users of DOACs and vitamin K antagonists.
  • Evaluated the composite outcome of adverse events including kidney transplant rejection.
  • DOACs were associated with a lower risk of the composite outcome compared to vitamin K antagonists.
  • Patients using DOACs experienced reduced rates of kidney transplant rejection.

Structured PICO

Do direct oral anticoagulants reduce the risk of composite outcomes and kidney transplant rejection in kidney transplant recipients with atrial fibrillation compared to Vitamin K antagonists?

P
Population
Kidney transplant recipients (KTRs) with atrial fibrillation (AF)
I
Intervention
Direct oral anticoagulants (DOACs)
C
Comparator
Vitamin K antagonist (VKA)
O
Outcome
Composite outcome and kidney transplant rejectioncomposite

In kidney transplant recipients with atrial fibrillation, DOACs are associated with a lower risk of adverse composite outcomes and transplant rejection compared to VKAs.

Abstract

In this real-world cohort of KTRs with AF, DOACs use was associated with lower risk of the composite outcome and kidney transplant rejection.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rossi et al. (2026) studied this question. DOACs use in kidney transplant recipients with atrial fibrillation was associated with lower risk of composite outcomes and kidney transplant rejection.

synapsesocial.com/papers/698c1bb8267fb587c655d8dehttps://doi.org/10.1016/j.ejim.2026.106751
Ask AI
Helpful
Bookmark
Share
View Full Paper